Clinical Edge Journal Scan

Severity of diabetes tied to lung cancer prognosis


 

Key clinical point : Patients with squamous cell lung carcinoma (SqCLC) and moderate-to-severe diabetes may have a higher risk for all-cause mortality than those with SqCLC and mild diabetes.

Major finding : Patients with SqCLC and moderate to severe diabetes had a 17% higher risk for all-cause death than those with SqCLC and mild diabetes (adjusted hazard ratio 1.17; P = .0005).

Study details : The data come from a retrospective cohort study including patients with both SqCLC and diabetes (n = 5742) from the Taiwan Cancer Registry database.

Disclosures: The study was funded by grants from Lo-Hsu Medical Foundation, LotungPoh-Ai Hospital, and Fu Jen Catholic University. The authors declared no conflicts of interest.

Source: Su C-H et al. Association of diabetes severity and mortality with lung squamous cell carcinoma. Cancers (Basel). 2022;14(10):2553 (May 22). Doi: 10.3390/cancers14102553

Recommended Reading

Extensive-stage SCLC: Anlotinib plus platinum-etoposide shows promise
MDedge Hematology and Oncology
Lung cancer: Noncancerous chest CT features may boost survival prediction
MDedge Hematology and Oncology
Lung cancer: Diagnostic method using breath biomarkers shows promise
MDedge Hematology and Oncology
Advanced squamous NSCLC: NFE2L2 and KEAP1 mutations tied to worse real-world PFS
MDedge Hematology and Oncology
Climate change and air pollution seen through the cancer lens
MDedge Hematology and Oncology
Can lung cancer ID be as easy as breathing into an analyzer?
MDedge Hematology and Oncology
Commentary: Genetic Components of NSCLC, June 2022
MDedge Hematology and Oncology
Immunotherapy treatment combo charts new course for resectable NSCLC treatment
MDedge Hematology and Oncology
Adagrasib shows durable benefit in KRAS-mutated NSCLC
MDedge Hematology and Oncology
Promising treatment option for incurable lung cancer described as ‘significant’
MDedge Hematology and Oncology